The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Treatment Intensification for Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/39486

At the conclusion of these activities, participants will be able to:
1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations.
2. Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy.
3. Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection.

This series is supported by independent educational grants from:
Astellas and Pfizer, Inc.
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.

REFERENCES:
Freedland SJ, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evidence. 2023.

Smith MR, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022.

Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022.

Clarke NW, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022

Chi KN, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023.

Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023.